Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Ingavirin Forte in Healthy Volunteers
NCT06859333Phase 1Recruiting
- Sponsor
- Valenta Pharm
- Start
- Jan 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of Ingavirin in influenza and viral respiratory infection (3 arms), sponsored by Valenta Pharm. Primary endpoints: Maximum Plasma Concentration, Time to Maximum Plasma Concentration and 3 more. Started Jan 2025; status: recruiting.
02
Drugs
Ingavirin
03
Conditions
influenzaviral respiratory infection
Beyond the preview
Go deeper on NCT06859333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06859333.